WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain.
Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1)]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see Warnings and Precautions (5.1)].
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see Dosage and Administration (2.3), Contraindications (4), Warnings and Precautions (5.1)]. If metformin-associated lactic acidosis is suspected, immediately discontinue metformin and institute general supportive measures in a hospital setting.
Prompt hemodialysis is recommended [see Warnings and Precautions (5.1)]. WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning. Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain.
Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. (5.1) Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment, and mitochondrial diseases.
Steps to reduce the risk of and manage metformin associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. (5.1) If lactic acidosis is suspected, discontinue Metformin Hydrochloride Tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.
(5.1)
Use: Labeled indications
- Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Metformin is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. (1)
Contraindications
- Severe kidney impairment (eGFR below 30 mL/min/1.73 m2)
- Hypersensitivity to metformin
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS Metformin Hydrochloride Tablets are contraindicated in patients with: Severe renal impairment (eGFR below 30 mL/min/1.73 m²) [see Warnings and Precautions (5.1)]. Hypersensitivity to metformin. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Severe renal impairment (eGFR below 30 mL/min/1.73 m²) (4, 5.1) Hypersensitivity to metformin (4) Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.(4)
Dosing: Adult
- Type 2 diabetes (immediate-release tablets): Start 500 mg twice daily or 850 mg once daily with meals; increase by 500 mg weekly or 850 mg every 2 weeks; maximum 2,550 mg/day in divided doses (doses above 2,000 mg may be better tolerated three times daily)
- Type 2 diabetes (extended-release products): Follow the product's own label (the Glumetza US label: start 500 mg once daily with the evening meal, maximum 2,000 mg once daily)
- Adult Dosage for Metformin Hydrochloride Tablets: Starting dose: 500 mg orally twice a day or 850 mg once a day, with meals (2.1)
- Increase the dose in increments of 500 mg weekly or 850 mg every 2 weeks, up to a maximum dose of 2550 mg per day, given in divided doses (2.1)
- Doses above 2000 mg may be better tolerated given 3 times a day with meals (2.1)
- Pediatric Dosage for Metformin Hydrochloride Tablets: Starting dose: 500 mg orally twice a day, with meals (2.2)
- Increase dosage in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses twice daily (2.2)
- Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (2.3)
- Do not use in patients with eGFR below 30 mL/minute/1.73 m² (2.3)
- Initiation is not recommended in patients with eGFR between 30-45 mL/minute/1.73 m² (2.3)
- Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m² (2.3)
- Discontinue if eGFR falls below 30 mL/minute/1.73 m² (2.3)
- Discontinuation for Iodinated Contrast Imaging Procedures: Metformin Hydrochloride Tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures (2.4)
2.1 Adult Dosage
2.1 Adult Dosage Metformin Hydrochloride Tablets The recommended starting dose of Metformin Hydrochloride Tablets is 500 mg orally twice a day or 850 mg once a day, given with meals. Increase the dose in increments of 500 mg weekly or 850 mg every 2 weeks on the basis of glycemic control and tolerability, up to a maximum dose of 2550 mg per day, given in divided doses.
Doses above 2000 mg may be better tolerated given 3 times a day with meals.
2.2 Pediatric Dosage for Metformin Hydrochloride Tablets
2.2 Pediatric Dosage for Metformin Hydrochloride Tablets The recommended starting dose of Metformin Hydrochloride Tablets for pediatric patients 10 years of age and older is 500 mg orally twice a day, given with meals. Increase dosage in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2000 mg per day, given in divided doses twice daily.
2.3 Recommendations for Use in Renal Impairment
2.3 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of Metformin Hydrochloride Tablets and periodically thereafter. Metformin Hydrochloride Tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m². Initiation of Metformin Hydrochloride Tablets in patients with an eGFR between 30 – 45 mL/minute/1.73 m² is not recommended.
In patients taking Metformin Hydrochloride Tablets whose eGFR later falls below 45 mL/min/1.73 m², assess the benefit risk of continuing therapy. Discontinue Metformin Hydrochloride Tablets if the patient’s eGFR later falls below 30 mL/minute/1.73 m² [see Warnings and Precautions (5.1)].
2.4 Discontinuation for Iodinated Contrast Imaging Procedures
2.4 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue Metformin Hydrochloride Tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m²; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart Metformin Hydrochloride Tablets if renal function is stable.
Dosing: Altered kidney function
Metformin is cleared by the kidneys, and the risk of lactic acidosis rises as kidney function falls. The US label contraindicates it below an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m2 and advises against starting it at eGFR 30 to 45; guidelines cap the dose at 1,000 mg/day if it is continued at eGFR 30 to 44.
Kidney function measure: Label uses eGFR (mL/min/1.73 m2).
Show full dosing details
- eGFR ≥60
- Usual dosing. Assess kidney function before starting and periodically (label).
- eGFR 30–59
- eGFR 45–59: usual dose; consider dose reduction if at high risk of lactic acidosis. eGFR 30–44: label advises not to start; if continuing, reduce to a maximum of 1,000 mg/day (KDIGO 2022; ADA-KDIGO 2022). Recheck eGFR every 3 to 6 months.
- eGFR 15–29
- Contraindicated (label). Stop if eGFR falls below 30.
- eGFR <15 (not on dialysis)
- Contraindicated (label).
- Hemodialysis (intermittent)
- Contraindicated (eGFR <30 per label).
- Peritoneal dialysis
- Contraindicated (eGFR <30 per label).
- CRRT
- Not appropriate; contraindicated in severe kidney impairment (label).
- Dialyzable? Yes: dialyzable with clearance up to 170 mL/min under good hemodynamic conditions; hemodialysis may help remove drug in suspected overdose (label).
- Monitoring eGFR before starting and at least periodically; more often in older adults. Stop before or at the time of iodinated contrast in at-risk patients per label. Hold temporarily during acute illness with dehydration, sepsis, hypoxia or acute heart failure, during procedures with restricted food or fluid intake, and for acute kidney injury; restart when eating and kidney function is stable (label 5.1).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Immediate-release, 10 years and older: start 500 mg twice daily (label).
- eGFR 30–59
- As for adults: eGFR 45–59 usual dose with monitoring; eGFR 30–44 do not start, and if continuing use a maximum of 1,000 mg/day (KDIGO 2022; ADA-KDIGO 2022).
- eGFR 15–29
- Contraindicated (label contraindication at eGFR <30 applies to all patients).
- eGFR <15 (not on dialysis)
- Contraindicated (eGFR <30).
- Hemodialysis (intermittent)
- Contraindicated.
- Peritoneal dialysis
- Contraindicated.
- CRRT
- Not appropriate.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
2.3 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of Metformin Hydrochloride Tablets and periodically thereafter. Metformin Hydrochloride Tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m². Initiation of Metformin Hydrochloride Tablets in patients with an eGFR between 30 – 45 mL/minute/1.73 m² is not recommended.
In patients taking Metformin Hydrochloride Tablets whose eGFR later falls below 45 mL/min/1.73 m², assess the benefit risk of continuing therapy. Discontinue Metformin Hydrochloride Tablets if the patient’s eGFR later falls below 30 mL/minute/1.73 m² [see Warnings and Precautions (5.1)].
8.6 Renal Impairment Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. Metformin Hydrochloride is contraindicated in severe renal impairment, patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² [see Dosage and Administration (2.3), Contraindications (4), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)].
Renal Impairment In patients with decreased renal function the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased (see Table 3) [See Dosage and Administration (2.3), Contraindications (4), Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].
Dosing: Hepatic impairment
8.7 Hepatic Impairment Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. Metformin Hydrochloride is not recommended in patients with hepatic impairment. [see Warnings and Precautions (5.1)].
US FDA labelDosing: Pediatric
- Approved ages
- Immediate-release: type 2 diabetes, 10 to 16 years studied; not established under 10 years (label 8.4).
- Usual dose
- Immediate-release, 10 years and older: start 500 mg twice daily with meals; increase by 500 mg weekly (label 2.2).
- Maximum dose
- 2,000 mg/day in two divided doses (immediate-release, label).
- Neonates
- Neonates: specialist input.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use Metformin Hydrochloride Tablets The safety and effectiveness of Metformin Hydrochloride Tablets for the treatment of type 2 diabetes mellitus have been established in pediatric patients 10 to 16 years old. Safety and effectiveness of Metformin Hydrochloride have not been established in pediatric patients less than 10 years old.
Use of Metformin Hydrochloride Tablets in pediatric patients 10 to 16 years old for the treatment of type 2 diabetes mellitus is supported by evidence from adequate and well-controlled studies of Metformin Hydrochloride Tablets in adults with additional data from a controlled clinical study in pediatric patients 10 to 16 years old with type 2 diabetes mellitus, which demonstrated a similar response in glycemic control to that seen in adults [see Clinical Studies (14.1)]. In this study, adverse reactions were similar to those described in adults.
A maximum daily dose of 2000 mg of Metformin Hydrochloride Tablets are recommended. [See Dosage and Administration (2.2).]
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Controlled clinical studies of Metformin Hydrochloride Tablets did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients [see Warnings and Precautions (5.1)].
Dosage forms
Philippines
- Film-coated tablet: 1 g, 500 mg, 850 mg
- Extended-release tablet: 1 g, 500 mg, 750 mg
- Tablet: 1 g, 500 mg, 850 mg
- Prolonged-release tablet: 1 g, 500 mg
- Sustained-release tablet: 1 g, 500 mg
Registered products in the Philippines
243 products registered with the Food and Drug Administration (FDA) Philippines list Metformin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Metfomin Hydrochloride (1 product) · Metformin Hydrchloride (1 product) · Metformin Hyrdochloride (1 product). Products registered under these spellings are included in the table and marked.
All registered products243
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Aartmin 850Metformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Pinnacle Life Science Private Limited (Subsidiary of Aarti Drugs Limited)India | Khriz Pharma Trading Inc. | DR-XY49145 | Jul 31, 2029 | |
Aartmin 850Metformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Pinnacle Life Science Private Limited (Subsidiary of Aarti Drugs Limited)India | Khriz Pharma Trading Inc. | DRP-18047 | Jul 31, 2029 | |
AceforminMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | A.C.E.P. Medical Supplies Trading | DRP-12561-08 | Sep 2, 2027 | |
AzforMetformin Hydrochloride | 500 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-17804 | Mar 12, 2031 | |
BerametMetformin Hydrochloride | 500 mg TabletClear PVC-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Beracah Pharma Phils., Inc.Trader: Gamot Philippines, Inc. | DRP-5030 | Oct 12, 2030 | |
Bigsens XR 750Metformin hydrochloride | 750 mg Extended-Release TabletAlu/PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-11280 | Sep 24, 2029 | |
Bliformin-500Metformin hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sunrise International Labs LimitedIndia | Bliss Pharma Distribution and Consultancy Corp. | DRP-16837 | Jul 16, 2030 | |
Chemophase-500Metformin hydrochloride | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Merit Organics Ltd.India | Khriz Pharma Trading Inc. | DRP-15688 | Aug 27, 2029 | |
DiabaseMetformin Hydrochloride | 500 mg TabletClear PVC-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Basic Pharmaceutical CorporationTrader: Gamot Philippines, Inc. | DRP-5030-02 | Jul 14, 2031 | |
Diabemin XRMetformin hydrochloride | 1 g Extended-Release TabletAlu/PVC/PVDC blister pack x 10 tablets (box of 60 tablets) | RxVAT-exempt | PT. Ferron Par PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc.Trader: PT. Dexa Medica | DRP-11806 | May 2, 2027 | |
Diabemin XRMetformin Hydrochloride | 500 mg Extended-Release TabletAluminum/PVC/PVDC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | PT FERRON PAR PHARMACEUTICALSIndonesia | Glorious Dexa Mandaya, Inc.Trader: PT DEXA MEDICA | DRP-5511 | Oct 8, 2028 | |
Diabemin XRMetformin hydrochloride | 750 mg Extended-Release TabletAluminum/PVC/PVDC Blister Pack x 15's (Box of 30's and 60's) | RxVAT-exempt | PT Ferron Par PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc. | DRP-14124 | Jun 23, 2028 | |
DiafatMetformin hydrochloride | 1 g Film-Coated tabletAlu/clear PVC blister pack x 15 tablets (Box of 60's) | RxVAT-exempt | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-7389 | Oct 4, 2027 | |
DiafatMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10 Tablets (Box of 60 Tablets) | RxVAT-exempt | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-7388 | Oct 4, 2027 | |
DiametMetformin Hydrochloride | 500 mg Film-Coated TabletAlu / PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mercury Laboratories Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-14091-02 | Jun 20, 2028 | |
Diamet 500Metformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-4077-01 | Jun 24, 2027 | |
Diavin 500 XRMetformin Hydrochloride | 500 mg Extended-Release TabletAlu/Clear PVC Film Coated Tablet (Box of 30's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Medethix, Inc. | DRP-16523 | Apr 15, 2027 | |
Dimet-850Metformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Oman Pharmaceuticals Products Co., LLCSultanate | Madecs Pharma CorporationImporter: Atlantic Pharmaceuticals, Inc. | DR-XY40156 | Oct 11, 2036 | |
DMphage ER 500Metformin Hydrochloride | 500 mg Extended-Released TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Bafna Pharmaceutricals LimitedIndia | Amethyst Global (Philippines) Inc.Importer: Medethix, Inc. | DRP-15011-02 | Mar 13, 2031 | |
Emnorm ER 500Metformin Hydrochloride | 500mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | IPCA Laboratories LimitedIndia | Blue Global (FZE) | DRP-5659 | May 21, 2027 | |
Etromin 1000Metformin Hydrochloride | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: St. Raphael Archangel Pharmaceutical Product Distribution | DRP-14245 | Aug 2, 2030 | |
Etromin 500Metformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: St. Raphael Archangel Pharmaceutical Product Distribution | DRP-14247 | Aug 2, 2030 | |
Etromin 850Metformin hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: St. Raphael Archangel Pharmaceutical Product Distribution | DRP-14246 | Aug 2, 2030 | |
EuforminMetformin Hydrochloride | 1 g Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DRP-6873 | Mar 25, 2029 | |
EuforminMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DR-XY43317 | Mar 25, 2029 | |
ForedMetformin Hydrochloride | 500 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-4077-05 | Jun 24, 2027 | |
ForedMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mercury Laboratories Ltd.India | 777 Red Pharma Inc.Importer: Philgen Pharmaceuticals, Inc. | DRP-14091-01 | Jun 20, 2028 | |
ForherdinMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Medchoice Women’s Health (MCWH), Inc. | DRP-7406-06 | Jan 12, 2027 | |
FormetMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mercury Laboratories Ltd.India | Philgen Pharmaceuticals Inc. | DRP-14091 | Jun 20, 2028 | |
Formet 500Metformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 90's) [for DOH Supply] | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-4077 | Jun 24, 2027 | |
FormetinMetformin Hydrochloride | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 60's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Phil. Pharmawealth, Inc.Importer: Singapore Genebio, Inc. | DR-XY39832 | Jul 27, 2031 | |
FormexMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-8065 | May 6, 2029 | |
FormigenMetformin hydrochloride | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | Eba Generisch Trading Inc. | DRP-12562-05 | Sep 2, 2027 | |
FormigenMetformin hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | EBA Generisch Trading Inc. | DRP-12561-05 | Sep 2, 2027 | |
Formigen 1000Metformin hydrochloride | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: Eba Generisch Trading Inc. | DRP-14254 | Aug 4, 2030 | |
Formigen 500Metformin hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: Eba Generisch Trading Inc. | DRP-14256 | Aug 4, 2030 | |
Formigen 850Metformin hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Trader: Eba Generisch Trading Inc. | DRP-14255 | Aug 4, 2030 | |
ForniddMetformin Hydrochloride | 500 mg Film-Coated TabletAlu Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: sanofi-aventis Philippines Inc. | DRP-3033 | Feb 4, 2030 | |
1 g Extended-Release TabletAlu Clear PVC/PVDC Blister Pack x 10's (Box of 100's); Alu Clear PVC/PVDC Blister Pack x 20's (Box of 100's) | Rx | Inventia Healthcare LimitedIndia | Sanofi-Aventis Philippines, Inc.Importer: I.E. Medica, Inc. | DRP-3520 | Jan 30, 2027 | ||
Fornidd XRMetformin Hydrochloride | 500 mg Extended-Release TabletAlu/PVC/PVDC Blister Pack x 20's Box of 100's; Alu/Clear PVC/PVDC Blister Pack Box of 2's as physician's sample | RxVAT-exempt | Inventia Healthcare Ltd.India | Sanofi-Aventis, Philippines , Inc.Importer: I.E. Medica, Inc. | DRP-2501-01 | Sep 29, 2029 | |
GluceeminMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | CDMed Pharmaceutical and Medical SupplyImporter: Pharmakon Biotec Inc. | DRP-13845-05 | Apr 28, 2028 | |
GlucoformMetformin Hydrochloride | 500 mg TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Vendiz Pharmaceuticals, Inc. | DRP-2055 | Aug 5, 2028 | |
GlucominMetformin hydrochloride | 500 mg Film-Coated TabletAlu-Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Randril International Co., Inc. | DRP-12693 | Aug 7, 2031 | |
GlucophageMetformin Hydrochloride | 1 g TabletClear PVC/Aluminum Blister Strip x 15's (Box of 60's) | RxVAT-exempt | Merck SanteFrance | Merck, Inc. | DRP-6511 | Jun 7, 2027 | |
Glucophage ForteMetformin Hydrochloride | 850 mg Film-coated tablet | RxVAT-exempt | — | Importer: Merck, Inc. | DRP-6510 | Feb 1, 2027 | |
Glucophage XRMetformin hydrochloride | 1 g Extended-Release TabletClear PVC/PVDC Alu Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Merck SanteFrance | Merck, Inc. | DRP-6509 | Sep 3, 2030 | |
Glucophage XRMetformin Hydrochloride | 500 mg Extended-Release Tablet | RxVAT-exempt | PT. Merck TbkIndonesia | Merck, Inc. | DRP-15546 | Feb 10, 2031 | |
Glucophage XRMetformin hydrochloride | 500 mg Extended-Release TabletClear PVC/PVDC Alu Blister Pack x 15's (Box of 30's) | RxVAT-exempt | Merck SanteFrance | Merck, Inc. | DRP-6507 | Sep 3, 2030 | |
Glucophage XRMetformin Hydrochloride | 750 mg Extended-Release TabletAlu/PVC/PVDC Blister Pack x 15's (Box of 60's) | RxVAT-exempt | PT. Merck TbkIndonesia | Merck, Inc. | DRP-16842 | Jan 15, 2031 | |
Glucophage XRMetformin hydrochloride | 750 mg Extended-Release TabletAlu/PVC/PVDC Blister Pack x 15's (Box of 60's) | RxVAT-exempt | Merck SanteFrance | Merck, Inc. | DRP-6508 | Sep 3, 2030 | |
Glucosaph-GE850Metformin hydrochloride | 850 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17523 | Jan 19, 2031 | |
GlucosilMetformin Hydrochloride | 500mg TabletAlu-Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Drugmakers Laboratories, Inc.Philippines | — | DRP-9135 | Oct 20, 2027 | |
GlucosilMetformin Hydrochloride | 850 mg TabletAlu/Clear PVC Blister pack x 10's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories Inc.Philippines | — | DRP-8276 | Jul 30, 2031 | |
GlucostopMetformin Hydrochloride | 500 mg TabletClear PVC-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Gamot Philippines, Inc. | DRP-5030-01 | Jul 30, 2031 | |
GlucotinMetformin hydrochloride | 1 g Film-Coated TabletAlu-Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma inc.Trader: Gamot Philippines, Inc. | DR-XY38914 | Jan 4, 2031 | |
GlucotinMetformin Hydrochloride | 850 mg Film-Coated TabletAluminum/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Gamot Philippines, Inc. | DR-XY39669 | Jun 22, 2031 | |
GludinMetformin Hydrochloride | 500 mg Film-coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | MedChoice Endocrine Group, Inc. | DRP-7406-03 | Jan 12, 2027 | |
GludinMetformin Hydrochloride | 500 mg Film-Coated TabletAlu-PVC Blister pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Trader: Medchoice Endocrine Group, Inc. | DRP-7736 | Aug 17, 2030 | |
GludinMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Trader: Medchoice Endocrine Group, Inc. | DRP-7737 | Mar 16, 2031 | |
Gludin XRMetformin hydrochloride | 1 g Extended Release TabletAlu/PVC/PVDC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Medchoice Endocrine Group, Inc.Importer: AMB HK Enterprises Inc. | DRP-10477-02 | Sep 30, 2031 | |
Gluko-SMetformin hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Starpharm, Inc. | DRP-12561-06 | Sep 2, 2027 | |
GlumetMetformin Hydrochloride | 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10 Blister packs x 10 Tablets) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-12900 | Nov 16, 2027 | |
GlumetMetformin hydrochloride | 1 g Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Harman Finochem LimitedIndia | Unilab, Inc. | DRP-16505 | Apr 2, 2030 | |
GlumetMetformin Hydrochloride | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack of 15's (Box of 60'S) | RxVAT-exempt | Lek S.A.Poland | Unilab, Inc.Importer: Sandoz Philippines Corporation | DRP-7389-02 | Oct 4, 2027 | |
GlumetMetformin Hydrochloride | 1 g TabletAlu/Alu Foil Strip x 4's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-10044 | Sep 5, 2037 | |
GlumetMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lek S.A.Poland | UNILAB, Inc.Importer: Sandoz Philippines Corporation | DRP-7388-02 | Oct 4, 2027 | |
GlumetMetformin hydrochloride | 500 mg TabletStrip Foil x 4s (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DRP-10043 | May 31, 2030 | |
GlumetMetformin hydrochloride | 500 mg TabletAlu/Alu Blister Strip Foil x 10’s (Box of 100’s) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-18090 | May 4, 2031 | |
GlumetMetformin hydrochloride | 850 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Harman Finochem LimitedIndia | Unilab, Inc. | DRP-17514 | Jan 15, 2031 | |
GlumetMetformin Hydrochloride | 850 mg TabletFlex Foil x 4's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | UNILAB , Inc.Trader: Ritemed Phils., Inc. | DRP-9981-01 | May 13, 2031 | |
Glumet-XRMetformin Hydrochloride | 1 g Prolonged-Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | UNILAB, Inc. | DRP-13868 | May 5, 2028 | |
Glumet-XRMetformin hydrochloride | 500 mg Extended-Release TabletStrip Foil x 4's Box of 100's | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-10042 | Feb 16, 2029 | |
GlumiraMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Shouguang Fukang Pharmaceutical Co., Ltd.China | Hexagon Pharmaceuticals | DRP-17497 | Jan 12, 2031 | |
Gluventa PR 1000Metformin hydrochloride | 1 g Prolonged-Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Healol Pharma Corporation | DRP-15097 | Apr 29, 2029 | |
Gluventa PR 500Metformin hydrochloride | 500 mg Prolonged-Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Healol Pharma Corporation | DRP-15098 | Apr 29, 2029 | |
Gluventa PR 750Metformin hydrochloride | 750 mg Extended-Release TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Healol Pharma Corporation | DRP-12015 | May 30, 2027 | |
GLYCELIFEMetformin hydrochloride | 500 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Life and Health Source Pharmaceutical Distribution Co.Importer: AMB HK Enterprises Inc. | DRP-11939-04 | May 20, 2027 | |
Glycemed 1000Metformin Hydrochloride | 1 g Extended-Release TabletAlu/PVC/PVDC Blister pack x 14's (Box of 28's) | RxVAT-exempt | Ind-Swift LimitedIndia | Medinova Pharmaceutical Inc. | DRP-15466 | Jul 11, 2029 | |
Glycemed 500Metformin Hydrochloride | 500 mg Extended-Release TabletAlu/ PVC/PVDC Blister pack x 14's (Box of 28's) | RxVAT-exempt | Ind-Swift LimitedIndia | Medinova Pharmaceutical Inc. | DRP-15468 | Jul 11, 2029 | |
Glycemed 750Metformin Hydrochloride | 750 mg Extended-Release TabletAlu-PVC Blister Pack by 14's | RxVAT-exempt | Ind-Swift LimitedIndia | Medinova Pharmaceutical Inc. | DRP-15467 | Jul 11, 2029 | |
GlycemetMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Cp., Ltd.China | AMB HK Enterprises Inc. | DRP-14853 | May 26, 2031 | |
GlycemetMetformin hydrochloride | 500mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-11939 | May 20, 2027 | |
GlyceminMetformin Hydrochloride | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Wallace Pharmaceuticals Pvt. Ltd.India | Hexagon Pharmaceuticals | DRP-15793 | Sep 18, 2029 | |
Glycemin SRMetformin Hydrochloride | 500 mg Sustained-Release TabletAlu/PVC Blister Pack (Box of 100's) | RxVAT-exempt | Wallace Pharmaceuticals Pvt. Ltd.India | Hexagon Pharmaceuticals | DRP-16326 | Feb 7, 2030 | |
GlyformetMetformin hydrochloride | 1 g Extended Release TabletAlu/PVC/PVDC Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc. | DRP-10477-01 | Sep 30, 2036 | |
GlyformetMetformin Hydrochloride | 1g Extended-Release TabletAlu Clear PVC/PVDC Blister Pack x 10's; (Box of 100's); Alu Clear PVC/PVDC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Inventia Healthcare Pvt. Ltd.India | Corbridge Group Phils., Inc.Importer: I.E. Medica, Inc. | DRP-3520-02 | Jan 30, 2027 | |
GlyformetMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY41497 | Dec 18, 2027 | |
GlyformetMetformin Hydrochloride | 850 mg Film-Coated TabletAlu-Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY40977 | Jun 21, 2027 | |
Glyminov 500Metformin (as hydrochloride) | 500 mg Film- Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Ratnaris Pharmaceuticals Private LimitedIndia | Medinova Pharmaceutical Inc. | DRP-18762 | Sep 1, 2031 | |
GlymoraMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-14853-05 | May 26, 2031 | |
GlyvexamedMetformin (as hydrochloride) | 500 mg Film- Coated TabletAlu/ Clear PVC Blister Pack x 10's (Box of 30's. Box of 100's) | RxVAT-exempt | Ratnaris Pharmaceuticals Private LimitedIndia | Medinova Pharmaceutical Inc. | DRP-18761 | Sep 1, 2031 | |
GMet 1000Metformin Hydrochloride | 1 g Prolonged Release TabletAlu-clear PVC/PVDC Blister Pack x 10's (Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Orange Biotec Inc. | DRP-13485 | Feb 27, 2028 | |
GMet 500Metformin Hydrochloride | 500 mg Prolonged release tabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Inventia Healthcare Limited.India | Orange Biotec Inc. | DRP-13694 | Apr 13, 2028 | |
GoforminMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-14853-01 | May 8, 2031 | |
HexametMetformin hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Shouguang Fukang Pharmaceutical Co., Ltd.China | Hexagon PharmaceuticalsTrader: Nanjing Pharmacare Co., Ltd. | DRP-13929 | May 18, 2028 | |
Hexamin SRMetformin Hydrochloride | 500 mg Sustained-Release TabletAlu/Amber PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Wallace Pharmaceuticals Pvt. Ltd.India | Hexagon Pharmaceuticals | DRP-16841 | Jul 16, 2030 | |
HovidEuformMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Hovid BerhadMalaysia | Hovid Inc. | DRP-6999 | Mar 7, 2031 | |
HovidEuform XRMetformin hydrochloride | 500 mg Extended-Release TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hovid BerhadMalaysia | Hovid Inc. | DR-XY45052 | Feb 10, 2031 | |
HumametMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 60’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: A. Menarini Philippines, Inc. | DR-XY24394 | May 15, 2031 | |
HumametMetformin Hydrochloride | 850 mg TabletPVC/PE/PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | HIZON LABORATORIES, INC.Philippines | Trader: A.MENARINI PHILIPPINES, INC. | DR-XY28729 | Jun 27, 2028 | |
Humamet®Metformin Hydrochloride | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 30's, 60's and 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | A. Menarini Philippines, Inc.Trader: Gold Life Distribution Phils. Inc. | DRP-10086-02 | Feb 22, 2027 | |
HUMAMET®Metformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | A. Menarini Philippines, Inc.Trader: Dr. Zen's Research Inc. | DRP-16851-01 | Dec 18, 2027 | |
I-MaxMetformin Hydrochloride | 500 mg Film-Coated tabletBlister pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Patriot Pharmaceuticals Corporation | DR-XY38629 | Oct 13, 2030 | |
LifemetMetformin Hydrochloride | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: Gold Life Distribution Phils. Inc. | DRP-10086 | Feb 22, 2032 | |
MaximetMetformin hydrochloride | 500 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Trumed PharmaceuticalsImporter: AMB HK Enterprises Inc. | DRP-11939-03 | May 20, 2027 | |
MaximetMetformin Hydrochloride | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Wallace Pharmaceuticals Pvt. Ltd.India | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-15793-01 | Sep 18, 2029 | |
MeclorminMetformin hydrochloride | 500mg Film-Coated TabletPVC/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Swiss Parenterals, Inc.India | International Apex Pharmaceuticals, Inc. | DR-XY47498 | Nov 17, 2026Past listed date | |
Medformin-500Metformin hydrochloride | 500mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Acme Formulation Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-13465 | Feb 23, 2028 | |
MedgluMetformin hydrochloride | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY39377 | May 9, 2031 | |
MeforinMetformin Hydrochloride | 500mg TabletAlu/PVC Blister Pack x 10's (Box of 10 Blister packs x 10 Tablets) | RxVAT-exempt | Celogen Generics Private Ltd.India | Endure Medical, Inc. | DR-XY48451 | Nov 7, 2027 | |
MelforMetformin Hydrochloride | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | Amiel Trading Inc. | DRP-12562-06 | Sep 2, 2027 | |
Melmet SR 1000Metformin Hydrochloride | 1 g Sustained Release TabletAlu/PVC Blister Pack x 10's (Box of 30's); Alu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DR-XY43079 | Mar 17, 2029 | |
Melmet SR 500Metformin Hydrochloride | 500 mg Sustained Release tabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-5797 | Jul 31, 2029 | |
Melmet-850Metformin (as hydrochloride) | 850 mg Film Coated TabletBlister Pack x 10's (Box of 50's and 100's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-1869 | Jul 9, 2031 | |
Met-A-DayMetformin Hydrochloride | 1 g Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-10136 | Oct 18, 2028 | |
MetagoldMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Brilliantmeed, Inc. | DRP-12561-12 | Sep 2, 2027 | |
MetcoreMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Acme Formulation Pvt Ltd.India | Triple Tact Import & Export Corp. | DRP-12807 | Oct 7, 2027 | |
MetfnMetformin hydrochloride | 1 g Film-Coated TabletAlu/PVC/PVDC blister pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK ENTERPRISES INC. | DRP-10479 | Sep 30, 2031 | |
MetfnMetformin Hydrochloride | 500mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-13560 | Mar 9, 2028 | |
MetfnMetformin Hydrochloride | 850 mg Film-coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-13806 | Apr 27, 2028 | |
Metfor PR 1000.Metformin hydrochloride | 1 g Prolonged Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | USV Private LimitedIndia | The Cathay YSS Distributors Co., Inc. | DR-XY48463 | Nov 14, 2027 | |
Metfor XRMetformin Hydrochloride | 500 mg Extended-Release TabletAlu/PVC/PVDC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | The Cathay Yss Distributors Co., Inc.Importer: AMB HK Enterprises Inc. | DRP-10478-01 | Sep 30, 2031 | |
Metfor XRMetformin hydrochloride | 750 mg Extended Release TabletStrip Foil x 6's (Box of 30's) | RxVAT-exempt | El Laboratories, IncPhilippines | Trader: The Cathay YSS Distributors Co., Inc. | DR-XY44791 | Feb 9, 2031 | |
Metfor XRMetformin hydrochloride | 750 mg Extended-Release TabletAluminum/PVC/PVDC Blister Pack x 15’s (Box of 30’s) | RxVAT-exempt | PT Ferron Par PharmaceuticalsIndonesia | The Cathay YSS Distributors Co., Inc.Importer: Glorious Dexa Mandaya, Inc.Trader: PT Dexa Medica | DRP-14124-01 | Jun 23, 2028 | |
MetforedMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. LtdIndia | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-6686-01 | May 4, 2031 | |
METFOREDMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s); Alu/PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | 777 RED PHARMA INC.Importer: Nelpa Lifesciences, Inc. | DRP-6686-03 | Mar 23, 2032 | |
MetformixMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hiral Labs LimitedIndia | Aglobal Care, Inc. | DRP-13470 | Feb 28, 2028 | |
MetforzeMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-13723 | Mar 31, 2028 | |
MetokonMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-13845 | Apr 28, 2028 | |
MetoxedMetformin Hydrochloride | 500 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc | DRP-17358 | Nov 20, 2030 | |
Metpen-850Metformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Pinnacle Life Science Private Limited (Subsidiary of Aarti Drugs Limited)India | A. Pendragon International Distribution OpcImporter: Khriz Pharma Trading Inc. | DRP-18047-01 | Jul 31, 2029 | |
Metpro-1000Metformin Hydrochloride | 1 g Prolonged-Release TabletAlu-clear PVC/PVDC Blister Pack x 10's (Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Preventia Healthcare Inc.Importer: Orange Biotec Inc. | DRP-13485-01 | Feb 27, 2028 | |
MetrolMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVDC/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Meedpharma Medical Supplies & Equipment DistributorTrader: Vamsler Phils. Incorporated | DR-XY44868 | Oct 15, 2031 | |
MetrometMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Metro Pharma Philippines Inc. | DRP-7406-05 | Jan 12, 2027 | |
MetstanMetformin Hydrochloride | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Westfield Pharmaceuticals, Inc.Trader: Gold Life Distribution Phils. Inc. | DRP-10086-1 | Feb 22, 2027 | |
MetsureMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Rule Med Pharma CorpImporter: Pharmakon Biotec Inc. | DRP-13845-02 | Apr 28, 2028 | |
Metta SRMetformin hydrochloride | 500 mg Extended-Release TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DRP-2445 | Sep 6, 2030 | |
MetterMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-12561-09 | Sep 2, 2027 | |
Metxr 1000Metformin hydrochloride | 1 g Extended Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-10477 | Sep 30, 2036 | |
Metxr 500Metformin hydrochloride | 500 mg Extended Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-10478 | Sep 30, 2031 | |
Metzan 850Metformin Hydrochloride | 850 mg Film-Coated TabletAlu / Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical and Pharma Inc. | DRP-14246-01 | Aug 2, 2030 | |
Metzan-500Metformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical and Pharma Inc. | DRP-12561-10 | Sep 2, 2027 | |
MetzenMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-14853-04 | May 25, 2031 | |
MymetMetformin Hydrochloride | 500mg Film-Coated TabletClear PVC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | New Myrex Laboratories, Inc.Bulacan | — | DRP-7448 | Nov 2, 2032 | |
NanometMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Nanomed Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-13845-04 | Apr 28, 2028 | |
Neoform 500Metformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | GX International, Inc. | DRP-7406-04 | Jan 12, 2027 | |
Neoform® 500Metformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | GX International, Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-8065-03 | May 6, 2029 | |
NeometMetformin hydrochloride | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Littman Drug Corporation | DR-XY39744 | Jul 22, 2031 | |
Nevox XRMetformin Hydrochloride | 500 mg Extended-Release TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | PT. Kalbe Farma TbkIndonesia | Globo Asiatico Enterprises, Inc. | DR-XY45817 | Mar 15, 2027 | |
NidcorMetformin hydrochloride | 500 mg Film-coated TabletFoil Strip x 10’s (Box of 100’s) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: PNSV Asia Corporation | DR-XY30095 | May 2, 2031 | |
NifrominMetformin hydrochloride | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12562-04 | Sep 2, 2027 | |
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12561-03 | Sep 2, 2027 | ||
NifrominMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product DistributionTrader: Eba Generisch Trading Inc. | DRP-14255-04 | Sep 19, 2031 | |
NimrofMetformin hydrochloride | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St.Raphael Archangel Pharmaceutical Product Distribution | DRP-12562-01 | Sep 2, 2027 | |
NimrofMetformin hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12561-01 | Sep 2, 2027 | |
NimrofMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product DistributionTrader: Eba Generisch Trading Inc. | DRP-14255-01 | Sep 22, 2031 | |
NoneMetformin Hydrochloride | 1 g Extended-Release TabletAlu Clear PVC/PVDC Blister Pack x 10's (Box of 100's); Alu Clear PVC/PVDC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Inventia Healthcare Pvt. Ltd.India | Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc. | DRP 3520-04 | Jan 30, 2027 | |
NoneMetformin Hydrochloride | 1 g Extended-Release TabletClear PVC/PVDC Alu Blister Pack x 10's Box of 60's | RxVAT-exempt | Merck SanteFrance | Philusa CorporationImporter: Merck, Inc. | DRP-6509-01 | Mar 20, 2027 | |
NoneMetformin Hydrochloride | 1 g Sustained-Release TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DR-XY42929 | Nov 12, 2028 | |
NoneMetformin Hydrochloride | 500 mg Extended-Release TabletAlu/Alu Blister Pack x 10’s Box of 30’s | RxVAT-exempt | Ipca Laboratories Ltd.India | International Pharmaceuticals, Inc.Importer: Blue Global (FZE) | DRP-5659-02 | May 21, 2027 | |
NoneMetformin Hydrochloride | 500 mg Extended-Released TabletAlu / Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Bafna Pharmaceutricals LimitedIndia | Patriot Pharmaceuticals CorporationImporter: Medethix, Inc. | DRP-15011-01 | Mar 13, 2031 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 90's & 100's) | RxVAT-exempt | Celogen Pharma Pvt. Ltd.India | Endure Medical, Inc. | DR-XY46324 | May 2, 2028 | |
NoneMetformin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 50's); Alu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Metz Pharmaceuticals, Inc. | DR-XY46558 | Apr 30, 2029 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletAlu-Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | St. Joseph DrugstoreTrader: Randril Internation Co., Inc. | DRP-12693-01 | Jun 2, 2031 | |
NoneMetformin hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Acme Formulation Pvt. Ltd.India | MED4UImporter: Medinova Pharmaceutical Inc. | DRP-13465-01 | Feb 23, 2028 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Reta DrugImporter: Pharmakon Biotec Inc. | DRP-13845-06 | Apr 28, 2028 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Cyden Medicale Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13845-08 | Apr 28, 2028 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | PT. Merck TBKIndonesia | Philusa CorporationImporter: Merck, Inc. | DRP-6512-01 | Jan 19, 2028 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletClear PVC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | New Myrex Laboratories, Inc.Philippines | Farmacia Ni Dok, Inc. | DRP-7448-01 | Nov 2, 2027 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Actimed, Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-8065-02 | May 6, 2029 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletFoil Strip x 10's (Box of 100's) | RxVAT-exempt | Pascual Laboratories, Inc.Philippines | Pharex Health Corporation | DRP-8408 | Jul 13, 2028 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletFoil Strip x 10's (Box of 100's) | RxVAT-exempt | Pascual Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-8408-01 | Jul 13, 2028 | |
NoneMetformin Hydrochloride | 500 mg Film-Coated TabletFoil Strip x 10's (Box of 100's) | RxVAT-exempt | Pascual Laboratories, Inc.Philippines | South Star Drug | DRP-8408-02 | Jul 13, 2028 | |
NoneMetformin hydrochloride | 500 mg Film-Coated TabletsAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Trumed PharmaceuticalsImporter: AMB HK Enterprises, Inc. | DRP-11930-02 | May 20, 2027 | |
NoneMetformin hydrochloride | 500 mg Sustained-Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | USV Private LimitedIndia | RITEMED PHILS., INC. | DR-XY43094 | Dec 18, 2028 | |
NoneMetformin hydrochloride | 500 mg Sustained-Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | USV Private LimitedIndia | Ritemed Phils., Inc. | DRP-14732 | Dec 18, 2028 | |
NoneMetformin hydrochloride | 500 mg TabletFoil Strip x 4's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: Ritemed Phils., Inc. | DR-XY27415 | Mar 6, 2031 | |
NoneMetformin Hydrochloride | 500 mg TabletAlu/PVC Blister pack x 10’s (Box of 100’s) | RxVAT-exempt | Wallace Pharmaceuticals Pvt. Ltd.India | Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals | DRP-15793-02 | Sep 18, 2029 | |
NoneMetformin Hydrochloride | 500 mg TabletClear PVC-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Foramen Products CorporationTrader: Gamot Philippines, Inc. | DRP-5030-03 | Jul 20, 2031 | |
NoneMetformin Hydrochloride | 500 mg TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medico Remedies LimitedIndia | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-5363-01 | Jun 26, 2029 | |
NoneMetformin Hydrochloride | 500 mg TabletAlu/PVC Blister pack x 10's (Box of 90's, 100's and 30's) | RxVAT-exempt | Medico Remedies LimitedIndia | Medethix, Inc. | DRP-5364 | Jun 26, 2029 | |
NoneMetformin Hydrochloride | 500mg Film-Coated TabletClear PVC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | New Myrex Laboratories, Inc.Philippines | Steinbach Products Inc. | DRP-7448-02 | Nov 2, 2027 | |
NoneMetformin Hydrochloride | 750 mg Extended-Release TabletAlu/PVC/PVDC Blister Pack x 15's Box of 60's | RxVAT-exempt | Merck SanteFrance | Philusa CorporationImporter: Merck, Inc. | DRP-6508-01 | Jan 14, 2029 | |
NoneMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen’s Research, Inc. | DR-XY41499 | Dec 18, 2027 | |
NoneMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Celogen Pharma Pvt., Ltd.India | Endure Medical Inc. | DR-XY46325 | May 2, 2028 | |
NoneMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-16851 | Dec 18, 2027 | |
NoneMetformin Hydrochloride | 850 mg Film-Coated TabletPVC/Aluminum Blister Pack x 8's (Box of 120's) | RxVAT-exempt | P.T. Merck TBKIndonesia | Philusa CorporationImporter: Merck, Inc. | DRP-6510-01 | Feb 1, 2027 | |
NoneMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DRP-7686 | Feb 3, 2031 | |
NoneMetformin Hydrochloride | 850 mg TabletFlex Foil x 4's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: Ritemed Phils., Inc. | DRP-9981 | Sep 17, 2031 | |
NorgluminMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Northmed Pharma and Medical Supplies DistributionImporter: Pharmakon Biotec Inc. | DRP-13845-07 | Apr 28, 2028 | |
NormaxMetformin Hydrochloride | 500 mg Extended-Release TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Bell-Kenz Pharma Inc.Importer: I.E. Medica, Inc. | DRP-2501-03 | Sep 29, 2029 | |
Obimet 500Metformin Hydrochloride | 500 mg Extended-Release TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | I.E. Medica, Inc. | DRP-2501 | Sep 29, 2029 | |
500 mg Prolonged-Release TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100' s) | Rx | Inventia Healthcare LimitedIndia | Metro Drug, IncImporter: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences Limited Inc. | DR-XY48800 | Jun 30, 2028 | ||
Panfor SR-1000Metformin Hydrochloride | 1 g Sustained-release tabletAlu/Clear PVC/PVDC Blister x 20's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd. | DR-XY34573 | Mar 27, 2029 | |
Panfor SR-500Metformin Hydrochloride | 500mg Sustained-Release TabletAlu/Clear PVC/PVDC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd. | DR-XY34377 | Mar 13, 2030 | |
Philmet-500Metformin hydrochloride | 500 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-11939-01 | May 20, 2027 | |
Proglutrol 1000Metformin Hydrochloride | 1 g Extended-Release TabletAlu Clear PVC/PVDC Blister Pack x 10's (Box of 100's); Alu Clear PVC/PVDC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Healol Pharma CorporationImporter: I.E. Medica, Inc. | DRP-3520-03 | Jan 30, 2027 | |
Proglutrol 500Metformin Hydrochloride | 500 mg Extended-Release TabletAlu/PVC/PVDC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Inventia Healthcare Ltd.India | Healol Pharma CorporationImporter: I.E. Medica, Inc. | DRP-2501-04 | Sep 29, 2029 | |
RaforMetformin hydrochloride | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12562-02 | Sep 2, 2027 | |
RaforMetformin hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | ST. Raphael Archangel Pharmaceutical Product Distribution | DRP-12561-02 | Sep 2, 2027 | |
RaforMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product DistributionTrader: Eba Generisch Trading Inc. | DRP-14255-02 | Sep 22, 2031 | |
ReformMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Transcend Phils., Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-8065-01 | May 6, 2029 | |
RegimetMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-12561-13 | Sep 2, 2027 | |
SheforminMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/ Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Kain’s Trading Corp.Importer: Pharmakon Biotec Inc. | DRP-13845-03 | Apr 28, 2028 | |
SplendametMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Vitalink Health Products, Inc. | DR-XY43159 | Feb 4, 2029 | |
SucranormMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 4's Box of 40's | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DRP-6871 | Mar 25, 2029 | |
SucrolMetformin Hydrochloride | 500 mg tabletAlu/PVC Blister Pack x 10' s Box of 100's | RxVAT-exempt | Medico Remedies LimitedIndia | I.E. Medica, Inc. | DRP-5363 | Jun 26, 2029 | |
SugadropMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Primera Pharma Corporation | DR-XY38628 | Oct 13, 2031 | |
SugargoneMetformin hydrochloride | 500 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hiral Labs LimitedIndia | TGIF Pharmaceutical Trading Inc.Importer: Aglobal Care, Inc. | DRP-13470-01 | Feb 28, 2028 | |
SugartrolMetformin Hydrochloride | 1g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 Blister Packs x 10 Tablets; Box of 10 Blister Packs x 10 Tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-12562-07 | Sep 2, 2027 | |
SugartrolMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister pack x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-12561-11 | Sep 2, 2027 | |
SugartrolMetformin Hydrochloride | 850 mg Film-Coated TabletAlu / Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generish Trading Inc. | DRP-14246-02 | Aug 2, 2030 | |
Sukrivent 1000Metformin Hydrochloride | 1 g Prolonged Release TabletPVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Phagrosea Corporation | DRP-15799 | Sep 18, 2029 | |
Sukrivent 500Metformin Hydrochloride | 500 mg Prolonged Release TabletPVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Phagrosea Corporation | DRP-15798 | Sep 18, 2029 | |
SwitlesMetformin hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | Curecare Pharmaceutical Products Distribution | DRP-12561-07 | Sep 2, 2027 | |
TechnometMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | One technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc. | DRP-13845-01 | Apr 28, 2028 | |
Theomet-500Metformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC blister pack x 10’s Box of 100’s | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-8238 | Jun 18, 2029 | |
Theomet-500Metformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC blister pack x 10’s Box of 100’s | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-8238-01 | Jun 18, 2029 | |
ThorminMetformin hydrochloride | 1 g Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12562-03 | Sep 2, 2027 | |
ThorminMetformin hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 3 blister packs x 10 tablets; Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12561-04 | Sep 2, 2027 | |
ThorminMetformin Hydrochloride | 850 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | ST. RAPHAEL ARCHANGEL PHARMACEUTICAL PRODUCT DISTRIBUTIONTrader: Eba Generisch Trading Inc. | DRP-14255-03 | Sep 12, 2031 | |
UnbrandedMetformin Hydrochloride | 500 mg Extended-Release TabletAlu-Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Torrent Pharmaceuticals, Ltd.India | TGP Pharma, Inc.Importer: Torrent Pharma Philippines, Inc. | DRP-2445-03 | Oct 20, 2031 | |
UnbrandedMetformin (as Hydrochloride) | 500 mg Film-Coated TabletAlu-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: Dyna Drug Corporation | DR-XY40446 | Dec 23, 2036 | |
UnbrandedMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Rizal | — | DR-XY45739 | Jan 12, 2037 | |
UnbrandedMetformin hydrochloride | 500 mg Film-Coated TabletAlu-Clear PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DR-XY46995 | Aug 7, 2030 | |
UnbrandedMetformin Hydrochloride | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | — | DRP-3156 | Aug 17, 2031 | |
UnbrandedMetformin Hydrochloride | 500 mg Film-Coated Tablet | RxVAT-exempt | Hizon Laboratories, Inc. | — | DRP-7406 | Jan 12, 2027 | |
UnbrandedMetformin Hydrochloride | 500 mg TabletAlu/PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | Medico Remedies LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc. | DRP-5363-02 | Jun 26, 2029 | |
UnbrandedMetformin Hydrochloride | 500mg Extended-Released TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Bafna Pharmaceutricals LimitedIndia | Medethix, Inc. | DRP-15011 | Mar 13, 2031 | |
UnbrandedMetformin Hydrochloride | 850 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | — | DRP-3292 | Oct 3, 2031 | |
VimetrolMetformin (as Hydrochloride) | 500 mg Film-Coated TabletAlu-PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Ultramed Pharma, Inc.Trader: Vamsler Phils. Incorporated | DR-XY40444 | Dec 23, 2031 | |
Xmet ER 500Metformin Hydrochloride | 500 mg Extended-Release TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Glenmark Pharmaceuticals Ltd.India | Glenmark Philippines, Inc. | DRP-8470 | Jan 26, 2032 | |
XometMetformin hydrochloride | 500mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-14888 | Jan 31, 2029 | |
Xrmin ER 1000.Metformin Hydrochloride | 1 g Extended-Release TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | Ambica International Corporation | DRP-15791 | Sep 18, 2029 | |
Xrmin ER 500Metformin Hydrochloride | 500 mg Extended-Release TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | Ambica International Corporation | DRP-15790 | Sep 18, 2029 | |
(no brand name)Metformin (as hydrochloride) | 1 g Extended Release TabletAlu/Clear PVC-PVdC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-17327 | Nov 14, 2030 | |
(no brand name)Metformin hydrochloride | 1 g Extended-Release TabletAluminum blister foil strip with Alcar thermoforming film x 10' s (Box of 100' s) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DR-XY48798 | Jun 30, 2028 | |
(no brand name)Metformin Hydrochloride | 1 g Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets) | RxVAT-exempt | United International Pharma Co. Ltd.Vietnam | RiteMED Phils., Inc.Trader: Concord Pharmaceutical Limited | DRP-12989 | Nov 16, 2027 | |
(no brand name)Metformin Hydrochloride | 1 g Prolonged-Release TabletAlu/Clear PVC/PVDC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Ind-Swift LimitedIndia | RiteMED Phils., Inc. | DRP-13780 | Apr 18, 2028 | |
(no brand name)Metformin hydrochloride | 500 mg Extended-Release TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-17477 | Jan 8, 2031 | |
(no brand name)Metformin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurica Laboratories Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-4077-04 | Jun 24, 2027 | |
(no brand name)Metformin Hydrochloride | 500 mg TabletAlu/Alu Blister Strip x 10's (Box of 100's) | RxVAT-exempt | United International Pharma Co. Ltd.Vietnam | Ritemed Phils., Inc. | DRP-12246 | Jul 11, 2027 | |
(no brand name)Metformin hydrochloride | 750 mg Extended-Release TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-17478 | Jan 8, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Metformin Hydrochloride Tablets, USP are available as: Metformin Hydrochloride Tablets, USP 500 mg are blackberry flavored, white to off-white, round, biconvex, beveled edge film coated tablets, debossed with ‘SG’ on one side ‘105’ on other side. Metformin Hydrochloride Tablets, USP 625 mg are blackberry flavored, White to off-white, modified capsule shape film coated tablets, debossed with ‘588’ on one side.
Metformin Hydrochloride Tablets, USP 750 mg are blackberry flavored, White to off-white, modified capsule shape film coated tablets, debossed with ‘589’ on one side. Metformin Hydrochloride Tablets, USP 850 mg are blackberry flavored, white to off-white, round, biconvex, beveled edge film coated tablets, debossed with ‘SG’ on one side ‘106’ on other side.
Metformin Hydrochloride Tablets, USP 1000 mg tablets are blackberry flavored, white to off-white, oval, biconvex, film coated tablets debossed on one side with S on the left side of bisect and G on the right side of bisect and other side 1 on the left side and 07 on the right side of the bisect. Metformin Hydrochloride Tablets, USP: 500 mg, 625 mg, 750 mg, 850 mg, and 1000 mg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Lactic Acidosis: See boxed warning. (5.1)
- Vitamin B12 Deficiency: Metformin may lower vitamin B12 levels. Measure hematological parameters annually and vitamin B12 at 2 to 3 year intervals and manage any abnormalities. (5.2)
- Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required (5.3)
5.1 Lactic Acidosis
5.1 Lactic Acidosis There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred with severe acidosis.
Metformin associated lactic acidosis was characterized by elevated blood lactate concentrations (>5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio; metformin plasma levels were generally >5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.
If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of Metformin Hydrochloride. In Metformin Hydrochloride Tablets treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions).
Hemodialysis has often resulted in reversal of symptoms and recovery. Educate patients and their families about the symptoms of lactic acidosis and, if these symptoms occur, instruct them to discontinue Metformin Hydrochloride Tablets and report these symptoms to their healthcare provider. For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below: Renal impairment— The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment.
The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient’s renal function include [see Dosage and Administration (2.1), Clinical Pharmacology (12.3)]: Before initiating Metformin Hydrochloride, obtain an estimated glomerular filtration rate (eGFR).
Metformin Hydrochloride is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m² [see Contraindications (4)]. Initiation of Metformin Hydrochloride is not recommended in patients with eGFR between 30-45 mL/min/1.73 m². Obtain an eGFR at least annually in all patients taking Metformin Hydrochloride. In patients at risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently.
In patients taking Metformin Hydrochloride whose eGFR falls below 45 mL/min/1.73 m², assess the benefit and risk of continuing therapy.
Drug interactions — The concomitant use of Metformin Hydrochloride with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance, or increase metformin accumulation. Consider more frequent monitoring of patients.
Age 65 or greater — The risk of metformin-associated lactic acidosis increases with the patient’s age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients.
Radiologic studies with contrast — Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop Metformin Hydrochloride at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m²; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.
Re-evaluate eGFR 48 hours after the imaging procedure, and restart Metformin Hydrochloride if renal function is stable.
Surgery and other procedures — Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension, and renal impairment. Metformin Hydrochloride should be temporarily discontinued while patients have restricted food and fluid intake.
Hypoxic states — Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may cause prerenal azotemia.
When such an event occurs, discontinue Metformin Hydrochloride Tablets.
Excessive alcohol intake — Alcohol potentiates the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake while receiving Metformin Hydrochloride Tablets.
Hepatic impairment — Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of Metformin Hydrochloride Tablets in patients with clinical or laboratory evidence of hepatic disease.
Mitochondrial Diseases — Metformin may increase the risk of lactic acidosis in patients with mitochondrial diseases such as mitochondrial encephalomyopathy with lactic acidosis, and stroke-like episodes (MELAS) syndrome and maternally inherited diabetes and deafness (MIDD). Metformin Hydrochloride Tablets are not recommended in patients with mitochondrial diseases such as MELAS syndrome and MIDD.
If a patient taking Metformin Hydrochloride Tablets develops elevated lactic acid levels (with or without accompanying neurologic signs and symptoms), discontinue Metformin Hydrochloride Tablets. Depending on the clinical context, consider evaluating the patient for MELAS, MIDD, or other mitochondrial disease.
5.2 Vitamin B12 Deficiency
5.2 Vitamin B12 Deficiency In Metformin Hydrochloride clinical trials of 29-week duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12 -intrinsic factor complex, may be associated with anemia but appears to be rapidly reversible with discontinuation of Metformin Hydrochloride or vitamin B12 supplementation.
Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B12 levels. Measure hematologic parameters on an annual basis and vitamin B12 at 2 to 3 year intervals in patients on Metformin Hydrochloride and manage any abnormalities [see Adverse Reactions (6.1)].
5.3 Hypoglycemia with Concomitant Use with Insulin
5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. Metformin Hydrochloride tablets may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with Metformin Hydrochloride Tablets [see Drug Interactions (7)].
5.4 Macrovascular Outcomes
5.4 Macrovascular Outcomes There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Metformin Hydrochloride Tablets.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide) | Adjust or monitor | Lower bicarbonate; higher lactic acidosis risk. | Consider more frequent monitoring. |
| OCT2/MATE inhibitors (ranolazine, vandetanib, dolutegravir, cimetidine) | Adjust or monitor | Higher metformin exposure; lactic acidosis risk. | Weigh benefits and risks of the combination. |
| Iodinated contrast | Adjust or monitor | Contrast-related kidney injury can lead to metformin accumulation and lactic acidosis. | May need to stop metformin around the procedure (see label 2.3). |
| Alcohol | Adjust or monitor | Potentiates metformin's effect on lactate. | Warn against excessive alcohol. |
| Insulin or insulin secretagogues | Adjust or monitor | More hypoglycemia. | Lower insulin or secretagogue doses may be needed. |
| Drugs that raise glucose (thiazides, corticosteroids, others) | Minor | Loss of glycemic control. | Watch glucose when starting or stopping them. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
7 DRUG INTERACTIONS Table 3 presents clinically significant drug interactions with Metformin Hydrochloride tablets. Table 3: Clinically Significant Drug Interactions with Metformin Hydrochloride Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.
Concomitant use of these drugs with Metformin Hydrochloride may increase the risk for lactic acidosis. Intervention: Consider more frequent monitoring of these patients. Examples: Topiramate, zonisamide, acetazolamide or dichlorphenamide. Drugs that Reduce Metformin Hydrochloride Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [Clinical Pharmacology (12.3)].
Intervention: Consider the benefits and risks of concomitant use with Metformin Hydrochloride. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine. Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin on lactate metabolism. Intervention: Warn patients against excessive alcohol intake while receiving Metformin Hydrochloride.
Insulin Secretagogues or Insulin Clinical Impact: Coadministration of Metformin Hydrochloride with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia. Intervention: Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin.
Drugs Affecting Glycemic Control Clinical Impact: Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. Intervention: When such drugs are administered to a patient receiving Metformin Hydrochloride, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Metformin Hydrochloride tablets, observe the patient closely for hypoglycemia.
Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring (7) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin.
Consider the benefits and risks of concomitant use (7) Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake (7)
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Drugs that Reduce Metformin Hydrochloride Clearance Clinical Impact: Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [ Clinical Pharmacology (12.3) ].
Adverse reactions
Common
- Diarrhea (53% vs 12% placebo)
- Nausea or vomiting (26% vs 8%)
- Flatulence (12% vs 6%)
- Asthenia (9% vs 6%)
- Indigestion (7%), abdominal discomfort (6%), headache (6%)
- Subnormal vitamin B12 (about 7% in 29-week trials)
Serious
- Lactic acidosis, sometimes fatal (boxed warning)
- Vitamin B12 deficiency
- Hypoglycemia with insulin or insulin secretagogues
- The following adverse reactions are also discussed elsewhere in the labeling: Lactic Acidosis [see Boxed Warning and Warnings and Precautions (5.1)] Vitamin B12 Deficiency [see Warnings and Precautions (5.2)] Hypoglycemia [see Warnings and Precautions (5.3)] For Metformin Hydrochloride Tablets, the most common adverse reactions (>5.0%) are diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact ScieGen at (855) 724-3436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
6.1 Clinical Studies Experience
6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Metformin Hydrochloride Tablets In a U.S. clinical trial of Metformin Hydrochloride in patients with type 2 diabetes mellitus, a total of 141 patients received Metformin Hydrochloride up to 2550 mg per day.
Adverse reactions reported in greater than 5% of Metformin Hydrochloride treated patients and that were more common than in placebo-treated patients, are listed in Table 1. Table 1: Adverse Reactions from a Clinical Trial of Metformin Hydrochloride Occurring >5% and More Common than Placebo in Patients with Type 2 Diabetes Mellitus Metformin Hydrochloride (n=141) Placebo (n=145) Diarrhea 53% 12% Nausea/Vomiting 26% 8% Flatulence 12% 6% Asthenia 9% 6% Indigestion 7% 4% Abdominal Discomfort 6% 5% Headache 6% 5% Diarrhea led to discontinuation of Metformin Hydrochloride in 6% of patients.
Additionally, the following adverse reactions were reported in ≥1% to ≤5% of Metformin Hydrochloride treated patients and were more commonly reported with Metformin Hydrochloride than placebo: abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing, palpitation. In Metformin Hydrochloride clinical trials of 29-week duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels was observed in approximately 7% of patients.
Pediatric Patients In clinical trials with Metformin Hydrochloride Tablets in pediatric patients with type 2 diabetes mellitus, the profile of adverse reactions was similar to that observed in adults.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of metformin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.
Adverse reaction frequency tables (US label) US FDA label
| Metformin Hydrochloride (n=141) | Placebo (n=145) | |
| Diarrhea | 53% | 12% |
| Nausea/Vomiting | 26% | 8% |
| Flatulence | 12% | 6% |
| Asthenia | 9% | 6% |
| Indigestion | 7% | 4% |
| Abdominal Discomfort | 6% | 5% |
| Headache | 6% | 5% |
Monitoring parameters
- eGFR before starting and at least periodically; more often in older adults. Stop before or at the time of iodinated contrast in at-risk patients per label. Hold temporarily during acute illness with dehydration, sepsis, hypoxia or acute heart failure, during procedures with restricted food or fluid intake, and for acute kidney injury; restart when eating and kidney function is stable (label 5.1). Kidney
- eGFR before starting and periodically (at least yearly; more often if at risk)
- Hematologic parameters yearly and vitamin B12 every 2 to 3 years (label 5.2)
- Hold for iodinated contrast per eGFR rules; recheck eGFR 48 hours after the procedure (label 2.4)
- Glycemic control
- Hold temporarily during acute illness with dehydration, sepsis, hypoxia or acute heart failure, during procedures with restricted food or fluid intake, and for acute kidney injury; restart when eating and kidney function is stable (label 5.1).
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Limited data with Metformin Hydrochloride in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see Data].
There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy [see Clinical Considerations]. No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 2-and 5times, respectively, a 2550 mg clinical dose, based on body surface area [see Data].
The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes mellitus with an HbA1C >7 and has been reported to be as high as 20–25% in women with a HbA1C >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly-controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.
Data Human Data Published data from post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups.
Animal Data Metformin hydrochloride did not adversely affect development outcomes when administered to pregnant rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 5 times a 2550 mg clinical dose based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.
Mechanism of action
12.1 Mechanism of Action Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
US FDA labelPharmacokinetics
Key PK parameters
| Bioavailability | About 50% to 60% (500 mg tablet, fasting); food lowers it slightly |
|---|---|
| Time to peak | About 2 to 3 hours (immediate-release; Tmax 1.8 to 3.3 hours in label Table 4) |
| Half-life | About 6.2 hours in plasma; about 17.6 hours in blood |
| Half-life in kidney failure (ESKD) kidney | Prolonged; not quantified in the label. Renal clearance about 108 to 130 mL/min at CLcr 10 to 60 vs about 550 to 640 mL/min in healthy adults (label Table 4) |
| Volume of distribution | 654 ± 358 L (V/F, 850 mg metformin HCl) |
| Protein binding | Negligible |
| Metabolism (CYP, transporters) | None (not metabolized) |
| Active metabolites | None |
| Renal excretion kidney | About 90% of absorbed drug renally within 24 hours (tubular secretion; renal clearance about 3.5 times CrCl) |
| Dialyzability kidney | Yes: clearance up to 170 mL/min under good hemodynamic conditions (label). |
Metabolism Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.
Elimination Renal clearance (see Table 4) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination.
Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours.
In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.
Specific Populations Renal Impairment In patients with decreased renal function the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased (see Table 3) [ See Dosage and Administration (2.3) , Contraindications (4) , Warnings and Precautions (5.1) and Use in Specific Populations (8.6) ] .
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption The absolute bioavailability of a metformin hydrochloride 500 mg tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin hydrochloride 500 to 1500 mg and 850 to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination.
At usual clinical doses and dosing schedules of metformin hydrochloride, steady state plasma concentrations of metformin are reached within 24 to 48 hours and are generally <1 μg/mL. Effect of food: Food decreases the extent of absorption and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (C max), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (T max) following administration of a single 850 mg tablet of Metformin Hydrochloride with food, compared to the same tablet strength administered fasting.
Distribution The apparent volume of distribution (V/F) of metformin following single oral doses of Metformin Hydrochloride 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time. Metabolism Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.
Elimination Renal clearance (see Table 4) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours.
In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution. Specific Populations Renal Impairment In patients with decreased renal function the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased (see Table 3) [See Dosage and Administration (2.3), Contraindications (4), Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].
Hepatic Impairment No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment [See Warnings and Precautions (5.1) and Use in Specific Populations (8.7)]. Geriatrics Limited data from controlled pharmacokinetic studies of metformin hydrochloride in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and C max is increased, compared to healthy young subjects.
It appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see Table 4). [See Warnings and Precautions (5.1) and Use in Specific Populations (8.5)]. Table 4: Select Mean (±S.D.) Metformin Pharmacokinetic Parameters Following Single or Multiple Oral Doses of Metformin Hydrochloride Tablets a All doses given fasting except the first 18 doses of the multiple dose studies b Peak plasma concentration c Time to peak plasma concentration d Combined results (average means) of five studies: mean age 32 years (range 23-59 years) e Kinetic study done following dose 19, given fasting f Elderly subjects, mean age 71 years (range 65-81 years) g CLcr = creatinine clearance normalized to body surface area of 1.73 m² Subject Groups: Metformin hydrochloride tablets dose a (number of subjects) C max b (mcg/mL) T max c (hrs) Renal Clearance (mL/min) Healthy, nondiabetic adults: 500 mg single dose (24) 850 mg single dose (74) d 850 mg three times daily for 19 doses e (9) 1.03 (±0.33) 1.60 (±0.38) 2.01 (±0.42) 2.75 (±0.81) 2.64 (±0.82) 1.79 (±0.94) 600 (±132) 552 (±139) 642 (±173) Adults with type 2 diabetes mellitus: 850 mg single dose (23) 850 mg three times daily for 19 doses e (9) 1.48 (±0.5) 1.90 (±0.62) 3.32 (±1.08) 2.01 (±1.22) 491 (±138) 550 (±160) Elderly f, healthy nondiabetic adults: 850 mg single dose (12) 2.45 (±0.70) 2.71 (±1.05) 412 (±98) Renal-impaired adults: 850 mg single dose Mild (CLcr g 61 to 90 mL/min) (5) Moderate (CLcr 31 to 60 mL/min) (4) Severe (CLcr 10 to 30 mL/min) (6) 1.86 (±0.52) 4.12 (±1.83) 3.93 (±0.92) 3.20 (±0.45) 3.75 (±0.50) 4.01 (±1.10) 384 (±122) 108 (±57) 130 (±90) Pediatrics After administration of a single oral metformin hydrochloride 500 mg tablet with food, geometric mean metformin C max and AUC differed less than 5% between pediatric type 2 diabetic patients (12-16 years of age) and gender-and weight-matched healthy adults (20-45 years of age), all with normal renal function.
Gender Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes mellitus when analyzed according to gender (males=19, females=16). Race No studies of metformin pharmacokinetic parameters according to race have been performed. Drug Interactions In Vivo Assessment of Drug Interactions Table 5: Effect of Coadministered Drug on Plasma Metformin Systemic Exposure Coadministered Drug Dose of Coadministered Drug * Dose of Metformin * Geometric Mean Ratio (ratio with/without coadministered drug) No Effect = 1.00 AUC † C max No dosing adjustments required for the following: Glyburide 5 mg 850 mg metformin 0.91 ‡ 0.93 ‡ Furosemide 40 mg 850 mg metformin 1.09 ‡ 1.22 ‡ Nifedipine 10 mg 850 mg metformin 1.16 1.21 Propranolol 40 mg 850 mg metformin 0.90 0.94 Ibuprofen 400 mg 850 mg metformin 1.05 ‡ 1.07 ‡ Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination Cimetidine 400 mg 850 mg metformin 1.40 1.61 Carbonic anhydrase inhibitors may cause metabolic acidosis [See Warnings and Precautions (5.1) and Drug Interactions (7).] Topiramate 100 mg § 500 mg § metformin 1.25 § 1.07 * All metformin and coadministered drugs were given as single doses † AUC = AUC(INF) ‡ Ratio of arithmetic means § At steady state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC = AUC 0-12h Table 6: Effect of Metformin on Coadministered Drug Systemic Exposure Coadministered Drug Dose of Coadministered Drug * Dose of Metformin * Geometric Mean Ratio (ratio with/without metformin) No Effect = 1.00 AUC † C max No dosing adjustments required for the following: Glyburide 5 mg 850 mg glyburide 0.78 ‡ 0.63 ‡ Furosemide 40 mg 850 mg furosemide 0.87 ‡ 0.69 ‡ Nifedipine 10 mg 850 mg nifedipine 1.10 § 1.08 Propranolol 40 mg 850 mg propranolol 1.01 § 1.02 Ibuprofen 400 mg 850 mg ibuprofen 0.97 ¶ 1.01 ¶ Cimetidine 400 mg 850 mg cimetidine 0.95 § 1.01 * All metformin and coadministered drugs were given as single doses † AUC = AUC(INF) unless otherwise noted ‡ Ratio of arithmetic means, p-value of difference <0.05 § AUC(0-24 hr) reported ¶ Ratio of arithmetic means
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Metformin Hydrochloride 500 mg Film coated tablet | ₱0.43–₱3.85Reference ₱0.54 | per tablet | DPRI procurement range |
| Metformin Hydrochloride 850 mg Tablet | ₱4.05–₱4.39Reference ₱4.39 | per tablet | DPRI procurement range |
| 500 mg (as hydrochloride) film-coated tablet | ₱4.75 | per tablet | PhilHealth GAMOT fixed fee |
| 500 mg (as hydrochloride) tablet | ₱4.75 | per tablet | PhilHealth GAMOT fixed fee |
| 850 mg (as hydrochloride) tablet | ₱5.25 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Metformin (as hydrochloride) |
| PNF listing | Oral: 500 mg tablet/film coated tablet 850 mg tablet |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
| PhilHealth YAKAP (formerly Konsulta) | Yes |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. METFORMIN HYDROCHLORIDE · ScieGen Pharmaceuticals Inc [US FDA-approved label, version 10, August 21, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e4c4ba9-65c6-4273-8f6b-2423ab521dad
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- ScieGen Pharmaceuticals Inc. (2026). Metformin hydrochloride tablets (metformin hydrochloride; immediate release) [Prescribing information; US FDA-approved label, ANDA203769, set ID 4e4c4ba9-65c6-4273-8f6b-2423ab521dad, version effective August 21, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e4c4ba9-65c6-4273-8f6b-2423ab521dad
- de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022). Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 45(12), 3075–3090. https://doi.org/10.2337/dci22-0027
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1–S127. https://doi.org/10.1016/j.kint.2022.06.008
- Santarus, Inc. (2026). Glumetza (metformin hydrochloride extended-release tablets) [Prescribing information; US FDA-approved label, NDA021748, set ID fb832474-88d9-4e29-95cd-fbc446944cc4, version effective September 2, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb832474-88d9-4e29-95cd-fbc446944cc4
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .



